Serology tests look for antibodies in the blood.
Antibodies are proteins that can fight off infections.
CDC is working with state, local, territorial, academic, and commercial partners to better understand COVID-19 in the United States. CDC has an overarching strategy for learning more about how many people have been infected with SARS-CoV-2, the virus that causes COVID-19, and how it is spreading through the U.S. population. This strategy includes using serology testing for surveillance to better understand how many infections with SARS-CoV-2 have occurred:
- At different points in time,
- In different locations, and
- Within different populations in the United States.
CDC is collaborating with public health and private partners on a variety of surveys of different sizes, locations, populations studied, and purposes. The seroprevalence surveys CDC is conducting include:
Serology tests look for antibodies in blood. If antibodies are found, that means there has been a previous infection. Antibodies are proteins that can fight off infections. Investigations using serology testing are called seroprevalence surveys. CDC is collaborating with public health and private partners on a variety of seroprevalence surveys of different sizes, locations, populations studied, and purposes. The seroprevalence surveys CDC is conducting include large-scale geographic surveys, community level surveys, and smaller-scale surveys focusing on specific populations in order to learn more about COVID-19.
Objectives of Surveillance of U.S. Serology Testing
- To provide a more complete estimate of how common COVID-19 is (or the incidence of infection)
- To guide control measures, such as social distancing
Serology testing surveillance provides important information
A key CDC priority is to track COVID-19 infections to determine how much of the U.S. population is infected over time. CDC uses a variety of surveillance systems to track COVID-19 cases based on people who seek medical care. However, these systems can miss infections that occur in people who had mild or asymptomatic illness (i.e., no signs or symptoms) who did not seek medical care or get tested.
By using seroprevalence surveys, CDC can learn about the total number of people that have been infected, including those infections that might have been missed. These surveys also can help estimate how much of the population has not yet been infected, helping public health officials plan for future healthcare needs. These surveys can also track how infections progress through the population over time. This is done by taking “snap shots” of the percentage of people who have antibodies against SARS-CoV-2 (also called the seroprevalence) at different time points.
Seroprevalence surveys also can look at risk factors for disease, such as a person’s age, location, or underlying health conditions. Finally, some kinds of seroprevalence surveys can determine how long antibodies last in people’s bodies following infection.